Welcome to our dedicated page for Establishment Labs Hldgs SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Establishment Labs’ march toward global regulatory approvals means digging through dense SEC documents and clinical data tables. Whether you want the latest cost breakdown of Motiva IDE trials or need to see when executives buy shares after a new CE-mark, our platform turns hours of research into minutes.
Start with the filings most investors ask for: the Establishment Labs quarterly earnings report 10-Q filing for production cost trends, the Establishment Labs annual report 10-K simplified for R&D pipeline details, and every Establishment Labs 8-K material events explained to track FDA milestones. Each document arrives in real time directly from EDGAR, then Stock Titan’s AI distills the medical device jargon so you can focus on numbers that move the model.
Need insider context? Our alerts surface Establishment Labs insider trading Form 4 transactions and display Establishment Labs Form 4 insider transactions real-time, highlighting option exercises or open-market buys that often precede material announcements. Governance questions are answered in the Establishment Labs proxy statement executive compensation, where AI flags pay structures tied to regulatory achievements.
- Compare manufacturing expansion costs across quarters with instant charts from the 10-Q.
- Monitor Establishment Labs executive stock transactions Form 4 for sentiment shifts.
- Use our narrative summaries for Establishment Labs earnings report filing analysis when modeling margins.
- Save time understanding Establishment Labs SEC documents with AI—no medical dictionary required.
From biocompatibility disclosures to litigation updates, Stock Titan provides Establishment Labs SEC filings explained simply, so analysts, clinicians, and long-term investors can act with confidence.
On 06/30/2025, Quest Resource Holding Corp. (QRHC) director Sarah Tomolonius reported the acquisition of 1,732 deferred stock units (DSUs) at an indicated price of $2.02 per unit, under the company’s 2024 Incentive Compensation Plan. These DSUs will convert into common shares when the director separates from the company.
After the transaction, Tomolonius beneficially owns 28,196 DSUs—18,027 granted in 2012 and 10,169 granted in 2024—plus 13,926 common shares held outright. Her total economic exposure therefore rises to approximately 42,122 shares. Ownership remains direct and no derivative securities were involved.
The purchase modestly increases insider alignment but is not material relative to QRHC’s overall share count or trading volume. No indication of a Rule 10b5-1 trading plan was disclosed, and no additional executive or strategic information accompanied the filing.
OP Bancorp (OPBK) – Form 4 filing: Chief Executive Officer and Director Sang Kyo Oh reported the grant of 29,326 restricted stock units (RSUs) on 1 July 2025. The RSUs convert into common shares on a one-for-one basis and vest in five equal annual tranches beginning one year from the grant date. No open-market purchases or sales of common stock were disclosed; the filing reflects an equity-based compensation award intended to align the CEO’s long-term incentives with shareholders. Following the grant, Oh directly holds 29,326 derivative securities (RSUs) and the corresponding right to receive an equivalent number of common shares as vesting occurs.
Schedule 13G Filing Overview – Enzo Biochem, Inc. (ENZ)
- Reporting group: Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and control person David A. Witkin.
- Ownership: The group reports 5,069,789 common shares, equal to 9.7 % of ENZ’s 52,432,129 shares outstanding as referenced in a 24 Jun 2025 merger agreement filing.
- Largest internal holder: Beryl Capital Partners II LP owns 4,088,352 shares (7.8 %).
- Voting & dispositive power: All shares are held with shared voting and dispositive power; none of the reporting persons has sole power.
- Filing nature: A Schedule 13G denotes a passive position — the securities are held in the ordinary course and not to change or influence control of the issuer.
- Trigger date: 24 Jun 2025; certification and signatures dated 1 Jul 2025 by COO Andrew Nelson and Mr. Witkin.
- Entity details: All entities are Delaware-organized; Beryl Capital Management LLC is investment adviser and general partner for the limited partnerships, with Mr. Witkin as the ultimate control person.
No financial results, transaction pricing, or additional strategic intentions are disclosed beyond the ownership data. The filing simply informs investors that a single institutional complex now controls just under 10 % of ENZ’s outstanding shares.
Schedule 13G Filing Overview – Enzo Biochem, Inc. (ENZ)
- Reporting group: Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and control person David A. Witkin.
- Ownership: The group reports 5,069,789 common shares, equal to 9.7 % of ENZ’s 52,432,129 shares outstanding as referenced in a 24 Jun 2025 merger agreement filing.
- Largest internal holder: Beryl Capital Partners II LP owns 4,088,352 shares (7.8 %).
- Voting & dispositive power: All shares are held with shared voting and dispositive power; none of the reporting persons has sole power.
- Filing nature: A Schedule 13G denotes a passive position — the securities are held in the ordinary course and not to change or influence control of the issuer.
- Trigger date: 24 Jun 2025; certification and signatures dated 1 Jul 2025 by COO Andrew Nelson and Mr. Witkin.
- Entity details: All entities are Delaware-organized; Beryl Capital Management LLC is investment adviser and general partner for the limited partnerships, with Mr. Witkin as the ultimate control person.
No financial results, transaction pricing, or additional strategic intentions are disclosed beyond the ownership data. The filing simply informs investors that a single institutional complex now controls just under 10 % of ENZ’s outstanding shares.
The Form 4 filing reports a routine equity compensation transaction for Establishment Labs Holdings Inc. (ESTA) director Nicholas Sheridan Lewin. On 30 June 2025, Lewin elected to receive 585 common shares in lieu of his quarterly cash retainer, valued at $42.71 per share under the company’s Outside Director Compensation Policy and issued from the 2018 Equity Incentive Plan. Following the grant, Lewin’s direct ownership increased to 1,075,923 shares, while he also indirectly owns 14,190 shares held by his spouse. No derivative securities were involved, and there were no dispositions. The filing indicates continued board-level alignment with shareholders but does not represent a material change in Lewin’s overall stake or the company’s share structure.
OSI Systems Inc. (OSIS) Form 4 filing: Executive Chairman and Director Deepak Chopra reported the purchase of 75 common shares on 06/30/2025 at $140.61 per share through the company’s Employee Stock Purchase Plan. Following the transaction, Chopra’s direct holdings increased to 330,703 shares. No derivative securities were involved and there were no dispositions. The filing reflects routine participation in an employee plan and represents less than 0.1% of Chopra’s total ownership, indicating limited financial impact on the company’s capitalization.
FAQ
What is the current stock price of Establishment Labs Hldgs (ESTA)?
What is the market cap of Establishment Labs Hldgs (ESTA)?
What is the primary business of Establishment Labs Holdings Inc?
How does the company ensure the safety and quality of its products?
Who are the main customers of Establishment Labs?
What distinguishes its implants from those of competitors?
How is innovation emphasized within the company?
In which geographic regions does Establishment Labs operate?
